Asako Nagata

机构：Pfizer (United States) · ORCID：0000-0003-3047-3207

发表论文 24 篇 · 总被引 1549 次 · h-index 14

代表论文

• Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance (2016 · Molecular Cancer Therapeutics · 被引 435)
• Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance (2013 · Proceedings of the National Academy of Sciences · 被引 283)
• Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor (2021 · Cancer Cell · 被引 194)
• Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer (2021 · Journal of Medicinal Chemistry · 被引 121)
• Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants (2016 · Journal of Medicinal Chemistry · 被引 94)
• Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR (2017 · Journal of Medicinal Chemistry · 被引 91)